Indikator likuiditas cepet Trevena Inc (TRVN)

Olinvyk's pricing policy is constrained by strict hospital limits, forcing Trevena, Inc. (TRVN) to offer significant discounts to secure placement on approved drug lists. This chart of the asset's value helps track these processes, with the current indicator standing at 0.00. Revenues are based on the sale of a safe opioid substitute for inpatient facilities, while market capitalization growth relies on expansion in Asia and the development of treatments for pandemic-related complications.

Trevena, Inc. (TRVN) focuses on introducing Olinvyk into the inpatient anesthesiology segment as an alternative to opioids. This indicator measures the company's ability to settle short-term liabilities using cash and accounts receivable, completely ignoring illiquid inventory. The investor views this ratio as a financial stability filter during periods of high volatility. By analyzing the quick liquidity trajectory, one can determine the business's real margin of safety without accounting for obsolete inventory.